Single-Center 8-Years Clinical Follow-Up of Cladribine-Treated Patients From Phase 2 and 3 Trials-Reference-Cited by-同舟云学术

Single-Center 8-Years Clinical Follow-Up of Cladribine-Treated Patients From Phase 2 and 3 Trials

Published:2020-06-17 Issue: Volume:11 Page:
ISSN:1664-2295
Container-title:Frontiers in Neurology
language:
Short-container-title:Front. Neurol.

Author:

Moccia Marcello,Lanzillo Roberta,Petruzzo Martina,Nozzolillo Agostino,De Angelis Marcello,Carotenuto Antonio,Palladino Raffaele,Brescia Morra Vincenzo

Publisher

Frontiers Media SA

Subject

Clinical Neurology,Neurology

Reference22 articles.

1. Cladribine tablets' potential role as a key example of selective immune reconstitution therapy in multiple sclerosis;Boyko;Degener Neurol Neuromuscul Dis.,2018

2. Cladribine: mechanisms and mysteries in multiple sclerosis;Jacobs;J Neurol Neurosurg Psychiatry.,2018

3. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial;Leist;Lancet Neurol.,2014

4. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis;Giovannoni;N Engl J Med.,2010

5. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets;De Stefano;Mult Scler.,2018

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis;Current Medical Research and Opinion;2023-09-19

2. A prospective observational longitudinal study with a two-year follow-up of multiple sclerosis patients on Cladribine;Clinical Neurology and Neurosurgery;2023-09

3. Safety and efficacy of cladribine in multiple sclerosis: a systematic review and meta-analysis;Neurological Sciences;2023-04-17

4. Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence;Multiple Sclerosis and Related Disorders;2023-01

5. Cladribine treatment for highly active multiple sclerosis: Real-world clinical outcomes for years 3 and 4;Journal of Neuroimmunology;2022-11